scholarly journals Association of Coffee Consumption and Its Types According to Addition of Sugar and Creamer with Metabolic Syndrome Incidence in a Korean Population from the Health Examinees (HEXA) Study

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 920
Author(s):  
Li-Juan Tan ◽  
Hye Joo Jeon ◽  
SoHyun Park ◽  
Seong-Ah Kim ◽  
Kyungjoon Lim ◽  
...  

Coffee is widely consumed worldwide, and numerous studies indicate that coffee consumption may potentially affect the development of chronic diseases. Metabolic syndrome (MetS) may constitute a risk factor for chronic diseases. We aimed to prospectively evaluate the association between coffee consumption and MetS incidence. All participants were selected from the Health Examinees study. MetS was defined by the Adult Treatment Panel III criteria of the National Cholesterol Education Program. A multivariate Cox proportional hazards regression model was used to assess the relationship between coffee consumption and MetS incidence. In comparison with non-consumers, male moderate consumers (≤3 cups/day) showed a lower risk for low high-density lipoprotein cholesterol (HDL-C) (≤1 cup/day, hazard ratio (HR): 0.445, 95% confidence interval (CI): 0.254–0.780; 1–3 cups/day, HR: 0.507, 95% CI: 0.299–0.859) and high fasting blood glucose (FPG) (≤1 cup/day, HR: 0.694, 95% CI: 0.538–0.895; 1–3 cups/day, HR: 0.763, 95% CI: 0.598–0.972). Male 3-in-1 coffee (coffee with sugar and creamer) consumers also showed a lower risk for low HDL-C (HR: 0.423, 95% CI: 0.218–0.824) and high FPG (HR: 0.659, 95% CI: 0.497–0.874). These findings indicate a negative association between moderate coffee consumption and low HDL-C and high FPG among Korean male adults.

2020 ◽  
Vol 8 (A) ◽  
pp. 606-610
Author(s):  
Angelo Vasiliadis ◽  
George Charitoudis ◽  
Theofanis Kantas ◽  
George Giovanidis ◽  
George Biniaris

AIM: This study aimed to determine the relationship between CTS, metabolic syndrome and obesity and to compare the severity of CTS between patients with or without metabolic syndrome (MS) and patients with or without obesity. METHODS: In this prospective study, patients with clinical and electrophysiological confirmed diagnosis of CTS were included. The waist circumference, blood pressure, fasting blood glucose, fasting triglycerides and high/low density lipoprotein cholesterol levels were recorded. Patients were categorized having metabolic syndrome according to Adult Treatment Panel III definition, while body mass index was used to identify obesity. RESULTS: A total of 65 patients with a mean age of 58.91 ± 12.49 years were included. MS was found in 39 (60%) patients and obesity in 27 (41.5%) patients. The CTS was described as mild, moderate and severe in 8, 12 and 19 hands of those with MS and in 2, 6, and 18 of those without MS respectively (p = 0.207). There were no statistically significant results observed between BMI and the severity of CTS (p > 0.05). The mean waist circumference was 94.75 ± 7.36, 98.78 ± 9.64, 106.42 ± 10.78, 86.41 ± 6.77 for patients with MS+_O–, MS–O+_, MS+_O+_ _and MS–O– _respectively (p < 0.002). CONCLUSION: CTS appears to be more severe in patients with MS than in patients with obesity. Central obesity is one of the well-known risk factors for CTS, but components of MS may have a greater effect on the severity of CTS.


2020 ◽  
Author(s):  
Jeoffray Diendéré ◽  
Ahmed Kaboré ◽  
Jean Kaboré ◽  
Hermann Lanou ◽  
Habib Fofana ◽  
...  

Abstract Background: Accumulation of metabolic syndrome abnormal components dramatically increases the risk for cardiovascular diseases. This study aimed to assess the specific prevalence of abnormal components according to the urbanization gradient, gender and age, with the cumulative number of abnormalities in Burkinabè, using nationally representative data.Methods: Data of 4365 participants to the Burkina Faso 2013 Stepwise approach to Surveillance study were analysed, including sociodemographic parameters (with age-groups of 25-34; 35-44; 45-54 and 55-64y), components defined with the International Diabetes Federation criteria (waist circumference [WC], blood pressure [BP], high-density lipoprotein cholesterol [HDL-C], fasting blood glucose [FBG]). The urbanization gradient was the four quartiles of the regional urbanization rates.Results: Between quartiles, prevalences (%) of abnormal components significantly differed and the extremes were: 71.1-81.2 in men(♂), 75.9-81.2 in women(♀) for low HDL-C; 32.8-48.2(♂), 21.5-51.6(♀) for elevated BP; 3.4-7.3(♂), 30.8-45.5(♀) for high WC; 6.2-11.0(♂), 6.7-14.2(♀) for high FBG; 2.8-7.3(♂), 9.6-24.0(♀) for individuals who cumulated at least three abnormalities; and the extreme means in cumulative number of abnormalities were 1.3-1.5(♂), 1.4-1.9(♀). Between age-groups, prevalences significantly differed and the extremes were: 71.9-81.6(♂), 71.8-83.1(♀) for low HDL-C; 32.3-49.1(♂), 23.8-30.3(♀) for elevated BP; 2.0-14.0(♂), 24.8-65.3(♀) for high WC; 6.4-13.0(♂), 5.5-10.4(♀) for high FBG; 2.5-12.0(♂), 8.5-25.8(♀) for individuals who cumulated at least three abnormalities; and the extreme means in number of abnormalities were 1.2-1.4(♂), 1.4-1.9(♀).Conclusion: The low HDL-C was nationally prevalent and could serve as a background to the metabolic abnormalities’ accumulation, which worsened with the process of urbanization and demographic transition, and more severely in women.


2021 ◽  
Author(s):  
Rachel A Warren ◽  
Allie S Carew ◽  
Pantelis Andreou ◽  
Christine Herman ◽  
Andrew P Levy ◽  
...  

Objective: The haptoglobin (Hp)2-2 phenotype (~35-40% of people) is associated with increased oxidation and dysfunctional high-density lipoprotein (HDL) in hyperglycemia and may explain why drugs designed to pharmacologically raise HDL-cholesterol and lower triglycerides have not reliably prevented cardiovascular disease (CVD) in diabetes. We aimed to determine whether the effect of adding fenofibrate versus placebo to simvastatin on the risk of coronary artery disease (CAD) events depends on Hp phenotype in the ACCORD lipid trial (NCT00000620). <p>Research Design and Methods: Cox proportional hazards regression models quantitfied the relationship between fenofibrate therapy and CAD events in the ACCORD lipid trial in participants with the Hp2-2 phenotype (n=1,795) separately from those without (n=3,201). </p> <p>Results: Fenofibrate therapy successfully lowered the risk of CAD events in participants without the Hp2-2 phenotype (multivariable-adjusted hazard ratio: 0.74, 95% CI: 0.60-0.90, compared to no fenofibrate therapy) but not in participants with the Hp2-2 phenotype (1.16, 0.87-1.56, p, interaction=0.009). Subgroup analyses revealed that this protective effect of fenofibrate against CAD events among the non-Hp2-2 phenotype group was most effective in participants with severe dyslipidemia (p, interaction=0.01), and and in males (p, interaction= 0.02) with an increased CAD risk from fenofibrate treatment observed in females with the Hp2-2 phenotype (p, interaction= 0.002). </p> <p>Conclusions: The effect of fenofibrate added to simvastatin on risk of CAD events depends on Hp phenotype in the ACCORD lipid trial. </p>


2018 ◽  
Vol 1 (1) ◽  
pp. 43
Author(s):  
Dyah Peni Puspitasari ◽  
Budi Widodo ◽  
Jongky Hendro Prayitno

Backgrounds: Metabolic syndrome is a syndrome characterized by central obesity, high blood glucose or impaired glucose tolerance, dyslipidemia, and high blood pressure. Nearly 70% to 80% of Diabetes melitus (DM) population was diagnosed with metabolic syndrome. We aimed to present the data of frequency of metabolic syndrome in patients with DM for a basis of future research.Method: This is a descriptive study design on DM patients based on NCEP ATP III criteria. The data was collected from direct measurements and laboratory results of all DM patients: waist circumference, weight, height, and blood pressure of the subjects, triglyceride status (TG), high-density lipoprotein cholesterol (HDL-C) status, and fasting blood glucose status.Results: From 77 DM patients, results were obtained in this study were 69 (89.61%) patients with DM-metabolic syndrome  (DM-MetS) and 8 (10.39%) patients with DM-non-metabolic syndrome. From 69 patients with DM-MetS, 52 (75.36%) were female and 17 (24.64%) were male.Discussions: Based on NCEP ATP III criteria, the components profile of metabolic syndrome in women patients with DM-MetS were 96,15% central obesity, 88,46% hypertension, 70,37% low HDL levels and 44,44% hypertriglycerides. While, in men patients with DM-MetS were 70.59% central obesity, 88.24% in hypertension, 70% in the low HDL levels, and 30% hypertriglycerides. Based on the number of components, can be determined the frequency components of the metabolic syndrome were 73.91% on the three components, 14.49% on four components, and 11.59% at five components.Conclusion: A total of 69 (89.61%) patients with T2DM were diagnosed as metabolic syndrome.


2021 ◽  
Author(s):  
Rachel A Warren ◽  
Allie S Carew ◽  
Pantelis Andreou ◽  
Christine Herman ◽  
Andrew P Levy ◽  
...  

Objective: The haptoglobin (Hp)2-2 phenotype (~35-40% of people) is associated with increased oxidation and dysfunctional high-density lipoprotein (HDL) in hyperglycemia and may explain why drugs designed to pharmacologically raise HDL-cholesterol and lower triglycerides have not reliably prevented cardiovascular disease (CVD) in diabetes. We aimed to determine whether the effect of adding fenofibrate versus placebo to simvastatin on the risk of coronary artery disease (CAD) events depends on Hp phenotype in the ACCORD lipid trial (NCT00000620). <p>Research Design and Methods: Cox proportional hazards regression models quantitfied the relationship between fenofibrate therapy and CAD events in the ACCORD lipid trial in participants with the Hp2-2 phenotype (n=1,795) separately from those without (n=3,201). </p> <p>Results: Fenofibrate therapy successfully lowered the risk of CAD events in participants without the Hp2-2 phenotype (multivariable-adjusted hazard ratio: 0.74, 95% CI: 0.60-0.90, compared to no fenofibrate therapy) but not in participants with the Hp2-2 phenotype (1.16, 0.87-1.56, p, interaction=0.009). Subgroup analyses revealed that this protective effect of fenofibrate against CAD events among the non-Hp2-2 phenotype group was most effective in participants with severe dyslipidemia (p, interaction=0.01), and and in males (p, interaction= 0.02) with an increased CAD risk from fenofibrate treatment observed in females with the Hp2-2 phenotype (p, interaction= 0.002). </p> <p>Conclusions: The effect of fenofibrate added to simvastatin on risk of CAD events depends on Hp phenotype in the ACCORD lipid trial. </p>


2019 ◽  
Vol 150 (1) ◽  
pp. 118-127 ◽  
Author(s):  
Yunhee Kang ◽  
Kyueun Lee ◽  
Jieul Lee ◽  
Jihye Kim

ABSTRACT Background Evidence on the prospective association between grain consumption and metabolic syndrome (MetS) is lacking. Objective This study explored the association between grain intake by subtype or various combinations of grain intake and the risk of developing MetS in South Korean adults using data from a community-based prospective cohort study. Methods A total of 5717 participants (2984 men and 2733 women) aged 40–69 y without MetS were followed up for 10 y (2001–2012). Grain consumption was assessed using a semiquantitative FFQ at baseline (2001–2002) and a follow-up examination (2005–2006). A multivariate Cox proportional hazards model was used to examine the risk of incident MetS and its components according to grain consumption (&lt;1, 1 to &lt;3, or ≥3 servings/d) by sex. Results In total, 2218 participants (38.8%) developed MetS. Frequent consumers of whole grains (≥3 servings/d) had a lower risk of incident MetS (men—HR: 0.51; 95% CI: 0.41, 0.63; P  = 0.0001; women—HR: 0.73; 95% CI: 0.60, 0.90; P = 0.0029), whereas frequent consumers of refined grains had a higher risk of incident MetS (men—HR: 1.63; 95% CI: 1.31, 2.03; P &lt; 0.0001; women—HR: 2.25; 95% CI: 1.82, 2.78; P &lt; 0.0001) compared with rare consumers (&lt;1 serving/d). The combination of low whole grains (&lt;2 servings/d) and high refined grains (≥2 servings/d) was associated with a higher risk of MetS than the combination of high whole grains and low refined grains (men—HR: 1.21; 95% CI: 1.04, 1.41; P = 0.012; women—HR: 1.43; 95% CI: 1.23, 1.66; P &lt; 0.0001). Conclusions Higher consumption of whole grains was associated with lower risk of incident MetS, whereas higher refined-grain consumption was associated with a higher risk in a middle-aged and older Korean population.


Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Karol E Watson ◽  
Preethi Srikanthan ◽  
Pamela J Schreiner ◽  
Wendy Post ◽  
Gregory L Burke ◽  
...  

Background : In population studies high HDL is associated with fewer CHD events, however in certain people high HDL does not appear to protect and recent work suggests that HDL can become dysfunctional in settings of inflammation. Since Metabolic Syndrome (MetSyn) patients often have systemic inflammation, we hypothesized that high HDL might not be protective in this group. Methods : We analyzed data from 6,814 subjects in MESA; 2,362 of whom had MetSyn. Subjects were stratified by HDL into low (< 40), mid (40 –59) and high (≥ 60 mg/dL) groups. Outcomes were cIMT, coronary calcium (CAC), and CHD events over 3 years of follow up. Cox proportional hazards models assessed the association of HDL with CHD events. Results : In non-MetSyn subjects, outcomes were worst in the low HDL group and improved as HDL increased. In MetSyn subjects, however, an unexpected U-shaped relationship was seen. The most favorable results were in MetSyn subjects with mid HDL (40 –59), while worse outcomes were seen with either low (< 40) or high (≥ 60) HDL. cIMT was 1.23, 1.14 and 1.26 mm for low, mid and high HDL respectively (p mid vs. high = 0.04). Log e CAC was 4.63, 4.37 and 4.66 for low, mid and high HDL (p = 0.09). CHD rates were 3.7%, 1.8% and 4.1% for low, mid and high HDL (p = 0.027). In multivariate analysis, high (vs. mid) HDL remained associated with CHD events in MetSyn (HR 2.44 [1.03–5.82]). Conclusion : Although HDL is associated with decreased CHD in general populations, in certain people HDL doesn’t protect. In our data MetSyn subjects with HDL ≥ 60 had poorer outcomes than those with HDL 40 –59, which suggests that HDL-C is a complex marker that must be interpreted in light of a person’s metabolic profile and inflammatory status.


Stroke ◽  
2019 ◽  
Vol 50 (11) ◽  
pp. 3045-3050 ◽  
Author(s):  
Joseph J. Decker ◽  
Faye L. Norby ◽  
Mary R. Rooney ◽  
Elsayed Z. Soliman ◽  
Pamela L. Lutsey ◽  
...  

Background and Purpose— Metabolic syndrome (MetS), a prothrombotic state, is associated with an increased risk of atrial fibrillation (AF) and stroke. The CHA 2 DS 2 -VASc score does not account for the MetS components of prehypertension, prediabetes mellitus, abdominal obesity, elevated triglycerides, and low HDL (high-density lipoprotein). Data are limited on the association of MetS with stroke in AF, independent of CHA 2 DS 2 -VASc variables. Our aim was to identify MetS components associated with ischemic stroke in participants with AF in the ARIC study (Atherosclerosis Risk in Communities). Methods— We included 1172 participants with incident AF within 5 years of measurement of MetS components. MetS was defined by ATP criteria and International Diabetes Federation criteria. Incident ischemic stroke was physician adjudicated. Multivariable Cox proportional hazards regression was used to assess the association of MetS components with stroke. Results— After a median follow-up of 14.8 years, there were 113 ischemic stroke cases. Of the individual MetS components, low HDL was borderline associated with increased stroke risk (hazard ratio, 1.48 [95% CI, 0.99–2.21]) after adjustment for CHA 2 DS 2 -VASc variables while the remaining MetS variables were not associated with stroke risk. The presence of ≥3 components of MetS was not significantly associated with ischemic stroke after adjustment for CHA 2 DS 2 -VASc variables (hazard ratio, 1.38 [95% CI, 0.91–2.11]). The risk of stroke increased by 13% for each additional component of MetS; however, this association was borderline significant (hazard ratio, 1.13 [95% CI, 0.99–1.28]). Conclusions— The presence of MetS was not significantly associated with ischemic stroke after adjustment for CHA 2 DS 2 -VASc variables. Consideration of MetS is unlikely to improve stroke prediction in AF.


2019 ◽  
Vol 4 (3) ◽  

Background and objective: Metabolic syndrome (Meets) is a cluster of obesity, hyperglycemia, dyslipidemia and hypertension (HTN). Thyroid hormones play an important role in regulating energy homeostasis, carbohydrate, lipids and protein metabolism. Therefore the present study was an effort to investigate the influence of TSH levels in each component of patients with Meets in a population of Saudi Arabia. Design: We analyzed retrospectively 656 participants with MetS whom are between the ages 20 to 98 years. All patients were from the population of the Primary health centre at King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia. All data were collected on the basis of a review of electronic medical data. Patient who are pregnant were excluded. The reference range values of TSH 0.22-4.2 MIU/L, Free T4 12.0-22.0 pmol/L. TSH was divided into three groups; <1.5, 1.5-2.5 and >2.5-4.2. Metabolic risk factors were defined using the 2006 IDF criteria that define elevated triglyceride as ≥150 mg/dL (≥1.7 mmol/L) and reduced high density lipoprotein cholesterol (HDL) as <40 mg/dL (<1.03 mmol/L) for male and as <50 mg/dL (<1.29 mmol/L) for female. Elevated blood pressure was defined when the systolic blood pressure was ≥130 mm Hg and/or diastolic blood pressure was ≥85 mm Hg in addition to receiving any medication for HTN. Abnormal glucose metabolism was con¬sidered when HbA1c (≥5.7) or when patients were known to have type 2 diabetes mellitus (T2DM). The total number of cohort was separated on basis of age values into four groups: <40 years, 40-49 years, 50-59 years and ≥60 years. Results: 656 subjects with MetS were included. There were 86 (13.1% ) male and 570 (86.9%) were female with mean age 55.6 ±12.7 with mean body mass index 32.8 ± 7.2 kg/m2 . HbA1c>5.6 or T2DM, hypertension, triglyceride (≥1.7 mmol/l) and low HDL were present in 94 (14.3%), 354 (54.0%), 328 (50.2%) and 487 (74.2%) respectively. The mean TSH and FT4 values were 2.1 ±1.0 mIU/l and 15.4 ±3.1 pmol/l respectively. Patients with TSH (>2.5-4.2) were non-significantly younger and have significantly higher BMI compared to patients with TSH (<1.5) or TSH (1.5-2.5), 50.9 ±12.4 vs. 53.5 ±12.7 vs. 53.4 ±13.0 respectively, p=0.05 and 33.6 ± 8.2 vs. 31.7 ± 6.1 vs. 33.2 ± 7.0 respectively, p=0.01. Females compared to males were non-significantly predominant in patients with TSH (>2.5-4.2) compared to patients with TSH (<1.5) or TSH (1.5-2.5), 87.3 vs. 12.7%, 89.4 vs. 10.6% and 84.0 vs. 16.0%, p=0.2. Cases with HbA1c>5.6 or T2DM were significantly more prevalent in patients with TSH (>2.5-4.2) compared to TSH (<1.5) or TSH (1.5-2.5), 18.8% vs. 13.9% vs. 10.0 respectively, p=0.03. Cases with HTN were significantly less prevalent in patients with TSH (>2.5-4.2) compared to TSH (<1.5) or TSH (1.5-2.5), 46.3% vs. 54.3% vs. 61.6 respectively, p=0.005. Cases with serum triglyceride (≥1.7 mmol/l) were significantly more prevalent in patients with TSH (>2.5-4.2) compared to TSH (<1.5) or TSH (1.5-2.5), 57.6% vs. 44.9% vs. 47.2 respectively, p=0.02. Cases with low HDL were significantly more prevalent in patients with TSH (>2.5-4.2) compared to TSH (<1.5) or TSH (1.5-2.5), 85.1% vs. 74.9% vs. 71.1 respectively, p=0.002. Higher prevalence of HbA1c>5.6 or T2DM, low HDL , triglyceride (≥1.7 mmol/l) and HTN in patients with age 40-59 years compared to <40 years or more than 60 years, p<0.0001, p=0.4, p=0.02 and p=0.3 respectively. Conclusion: We found that an increase in serum TSH was positively correlated with components of metabolic syndrome and might be a risk factor for metabolic syndrome in Saudis. Further investigations are essential to further confirm the relationship between TSH and components of metabolic syndrome in Saudis as well as the underlying mechanism(s).


2021 ◽  
pp. 000486742110096
Author(s):  
Oleguer Plana-Ripoll ◽  
Patsy Di Prinzio ◽  
John J McGrath ◽  
Preben B Mortensen ◽  
Vera A Morgan

Introduction: An association between schizophrenia and urbanicity has long been observed, with studies in many countries, including several from Denmark, reporting that individuals born/raised in densely populated urban settings have an increased risk of developing schizophrenia compared to those born/raised in rural settings. However, these findings have not been replicated in all studies. In particular, a Western Australian study showed a gradient in the opposite direction which disappeared after adjustment for covariates. Given the different findings for Denmark and Western Australia, our aim was to investigate the relationship between schizophrenia and urbanicity in these two regions to determine which factors may be influencing the relationship. Methods: We used population-based cohorts of children born alive between 1980 and 2001 in Western Australia ( N = 428,784) and Denmark ( N = 1,357,874). Children were categorised according to the level of urbanicity of their mother’s residence at time of birth and followed-up through to 30 June 2015. Linkage to State-based registers provided information on schizophrenia diagnosis and a range of covariates. Rates of being diagnosed with schizophrenia for each category of urbanicity were estimated using Cox proportional hazards models adjusted for covariates. Results: During follow-up, 1618 (0.4%) children in Western Australia and 11,875 (0.9%) children in Denmark were diagnosed with schizophrenia. In Western Australia, those born in the most remote areas did not experience lower rates of schizophrenia than those born in the most urban areas (hazard ratio = 1.02 [95% confidence interval: 0.81, 1.29]), unlike their Danish counterparts (hazard ratio = 0.62 [95% confidence interval: 0.58, 0.66]). However, when the Western Australian cohort was restricted to children of non-Aboriginal Indigenous status, results were consistent with Danish findings (hazard ratio = 0.46 [95% confidence interval: 0.29, 0.72]). Discussion: Our study highlights the potential for disadvantaged subgroups to mask the contribution of urban-related risk factors to risk of schizophrenia and the importance of stratified analysis in such cases.


Sign in / Sign up

Export Citation Format

Share Document